Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study

Patients admitted to the intensive care unit (ICU) for coronavirus disease 2019 (COVID-19), following an infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seem to have an increased risk of thrombotic events (TE), both arterial and venous [ 1 , 2 , 3 ]. Even in the absence of high level of evidence, some centers have consequently modified their pharmacological thromboprophylaxis strategy toward intermediate or full-dose (therapeutic) preemptive anticoagulation (rather than prophylactic dosing) for routine care of COVID-19 patients [ 2 , 4 ], exposing them to a higher risk of hemorrhagic events (HE).